Why Is Sleep Disorder Device Provider Vivos Therapeutics Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Vivos Therapeutics Inc (NASDAQ:VVOS) received FDA 510(k) clearance for its CARE oral appliances to treat severe obstructive sleep apnea (OSA) in adults. This makes Vivos the first company to offer an alternative to CPAP or surgical neurostimulation implants for severe OSA patients. The approval follows previous clearance for treating mild-to-moderate OSA. Data showed significant improvement in 80% of severe OSA patients with an average treatment time of 9.7 months. VVOS stock surged 169.70% to $11.84.
November 29, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vivos Therapeutics Inc's stock price surged following FDA clearance for its CARE oral appliances to treat severe OSA, marking a significant milestone as an alternative to CPAP or surgery.
The FDA clearance is a significant positive development for Vivos Therapeutics, as it not only expands the potential market for their products but also positions the company as a pioneer in the treatment of severe OSA. The news is likely to increase investor confidence and could lead to increased demand for VVOS shares in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100